Elorac, Inc. Promotes Christopher Gabanski as Chief Commercial Officer
Published: Jul 22, 2011
In making the announcement, Mr. Bernstein said, “Chris has done an outstanding job growing our pharmaceutical business, and I am confident he will bring the same energy and innovative thinking to his new expanded role. I’ve worked collaboratively with Chris for many years to share strategic solutions and execute our successful plan. Chris’s leadership experience, combined with the great record he had as our Vice President of Sales & Marketing, uniquely qualifies him for this next important responsibility at Elorac. Chris has been my trusted colleague in building Elorac, and I know he has the complete respect and total support of our customers, vendors and staff.”
Before his promotion to Chief Commercial Officer, Mr. Gabanski served as Vice President of Sales and Marketing. Mr. Gabanski has over 30 years of executive leadership experience with a specialization in the field of pharmaceutical dermatology. He brings a track record of success establishing companies' commercial infrastructure, commercialization of product portfolios and worldwide business development initiatives with the dermatology community to Elorac, Inc. Starting his career in sales with Neutrogena becoming Regional Sales Director, he has also served as Director of Marketing and Sales with Baker/Cummins Pharmaceuticals, Vice President Marketing at Physicians Formula, Vice President Sales with GenDerm Corporation, Vice President Sales, Dermatology at Warner Chilcott and Director of Sales at Procyte Corporation. He earned his B.A. in Biology from Lake Forest College.
Elorac, Inc., based in Vernon Hills, IL, is a specialty pharmaceutical company engaged in the development and commercialization of novel prescription products for the advancement of skin care. By leveraging the extensive development and commercialization capabilities of its experienced management team, Elorac develops and commercializes unique prescription products with potentially significant improvements over current therapies in dermatology.
Elorac, Inc.Jeffrey Bernstein, 847-362-8200